Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BPMC 
Blueprint Medicines Corp (BPMC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/11/2025: BPMC (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 45.46% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/11/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.17B USD | Price to earnings Ratio - | 1Y Target Price 125 |
Price to earnings Ratio - | 1Y Target Price 125 | ||
Volume (30-day avg) 1168304 | Beta 0.75 | 52 Weeks Range 73.04 - 121.90 | Updated Date 04/13/2025 |
52 Weeks Range 73.04 - 121.90 | Updated Date 04/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -13.19% | Operating Margin (TTM) -28.15% |
Management Effectiveness
Return on Assets (TTM) -11.89% | Return on Equity (TTM) -31.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5019780929 | Price to Sales(TTM) 10.15 |
Enterprise Value 5019780929 | Price to Sales(TTM) 10.15 | ||
Enterprise Value to Revenue 9.87 | Enterprise Value to EBITDA 260.98 | Shares Outstanding 63906000 | Shares Floating 63174287 |
Shares Outstanding 63906000 | Shares Floating 63174287 | ||
Percent Insiders 0.87 | Percent Institutions 106.76 |
Analyst Ratings
Rating 4.05 | Target Price 125.58 | Buy 5 | Strong Buy 9 |
Buy 5 | Strong Buy 9 | ||
Hold 5 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Blueprint Medicines Corp
Company Overview
History and Background
Blueprint Medicines was founded in 2011. It focuses on developing kinase inhibitors for genomically defined cancers and other diseases. Key milestones include FDA approvals for its therapies and partnerships with pharmaceutical companies.
Core Business Areas
- Precision Oncology: Developing targeted therapies for cancer patients with specific genetic mutations.
- Systemic Mastocytosis: Development of treatments for systemic mastocytosis, a rare hematologic disorder.
Leadership and Structure
The leadership team consists of seasoned executives in the pharmaceutical industry. The organizational structure is centered around research and development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- Gavreto (pralsetinib): Gavreto is a RET inhibitor approved for certain types of lung and thyroid cancers. The RET inhibitor market is competitive, including drugs from Eli Lilly. Novartis acquired the rights to Gavreto outside the US. Market share is growing but is subject to fierce competition.
- Ayvakit (avapritinib): Ayvakit is a KIT inhibitor approved for advanced systemic mastocytosis and certain gastrointestinal stromal tumors (GIST). Competitors include imatinib. Ayvakit sales figures contribute significantly to the revenue. Number of users is steadily growing.
Market Dynamics
Industry Overview
The industry is characterized by rapid innovation in targeted therapies and personalized medicine. There is a strong demand for effective treatments for cancer and rare diseases.
Positioning
Blueprint Medicines is positioned as a leader in developing kinase inhibitors for genomically defined diseases, leveraging its expertise in drug discovery and development. Its competitive advantage lies in its targeted approach and focused pipeline.
Total Addressable Market (TAM)
The TAM for targeted cancer therapies is estimated to be in the tens of billions of dollars. Blueprint Medicines is targeting specific subsets within this market, positioning itself to capture a significant share with its approved therapies and pipeline candidates.
Upturn SWOT Analysis
Strengths
- Strong pipeline of targeted therapies
- FDA-approved products with proven efficacy
- Expertise in kinase inhibitor development
- Strategic partnerships with pharmaceutical companies
Weaknesses
- Reliance on a limited number of products
- Competition from larger pharmaceutical companies
- High research and development costs
- Dependence on regulatory approvals
Opportunities
- Expansion into new indications and markets
- Development of next-generation kinase inhibitors
- Collaboration with academic institutions and research centers
- Acquisition of complementary technologies
Threats
- Clinical trial failures
- Regulatory setbacks
- Patent expirations
- Emergence of competing therapies
- Pricing pressures
Competitors and Market Share
Key Competitors
- Eli Lilly (LLY)
- Novartis (NVS)
- Deciphera Pharmaceuticals (DCPH)
Competitive Landscape
Blueprint Medicines competes with other pharmaceutical companies in the targeted cancer therapy space. Its advantages include its expertise in kinase inhibitor development and its portfolio of approved products. Its disadvantages include its smaller size and limited resources compared to larger competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Blueprint Medicines' growth has been driven by the commercialization of its FDA-approved products and the advancement of its pipeline.
Future Projections: Future growth projections depend on the success of its pipeline candidates and continued commercial performance of its approved therapies. Analyst estimates vary.
Recent Initiatives: Recent strategic initiatives include expanding the indications for its approved products, advancing its pipeline of novel therapies, and exploring strategic partnerships.
Summary
Blueprint Medicines is a promising biotech company focused on targeted cancer therapies. Its strengths lie in its innovative pipeline and FDA-approved products. Potential weaknesses include competition and reliance on clinical trial success. The company needs to continue driving sales of existing products and successfully navigate the regulatory landscape to capitalize on its opportunities.
Similar Companies
DCPH
Deciphera Pharmaceuticals LLC
DCPH
Deciphera Pharmaceuticals LLC
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
NVS
Novartis AG ADR
NVS
Novartis AG ADR
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The data may not be entirely accurate or complete and is subject to change. Investment decisions should be made based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Blueprint Medicines Corp
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2015-04-30 | President, CEO & Director Ms. Kathryn Haviland M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 649 | |
Full time employees 649 | |||
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.